The pathophysiological role of receptor-interacting protein kinase 3 in cardiovascular disease.

Cardiovascular diseases Inflammation Myocardial hypertrophy Necroptosis Oxidative stress Receptor interacting protein kinase 3 (RIPK3)

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 17 02 2023
revised: 07 04 2023
accepted: 10 04 2023
medline: 17 8 2023
pubmed: 18 6 2023
entrez: 17 6 2023
Statut: ppublish

Résumé

Recent studies have found that receptor interacting protein kinase 3 (RIPK3) can mediate CaMK Ⅱ phosphorylation and oxidation, open mitochondrial permeability transition pore (mPTP), and induce myocardial necroptosis. The increased expression or phosphorylation of RIPK3 is one of the important markers of necroptosis; Inhibition of CaMK Ⅱ phosphorylation or oxidation significantly reduces RIPK3 mediated myocardial necroptosis; Studies have shown that necroptosis plays an important role in the occurrence and development of cardiovascular diseases; Using the selective inhibitor GSK '872 of RIPK3 can effectively inhibit the occurrence and development of cardiovascular diseases, and can reverse cardiovascular and cardiac dysfunction caused by overexpression of RIPK3. In this review, we provide a brief overview of the current knowledge on RIPK3 in mediating necroptosis, inflammatory response, and oxidative stress, and discussed the role of RIPK3 in cardiovascular diseases such as atherosclerosis, myocardial ischaemia, myocardial infarction, and heart failure.

Identifiants

pubmed: 37329707
pii: S0753-3322(23)00484-5
doi: 10.1016/j.biopha.2023.114696
pii:
doi:

Substances chimiques

Mitochondrial Permeability Transition Pore 0
Protein Kinases EC 2.7.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114696

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there is no conflict of interest regarding the publication of this paper. Conflict of interest statement The authors declare that they have no conflicts of interest.

Auteurs

Jingjing Zhang (J)

School of Medicine, Nantong University, Nantong, Jiangsu 226001, China.

Jianan Qian (J)

School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, China.

Wei Zhang (W)

School of Medicine, Nantong University, Nantong, Jiangsu 226001, China; School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, China. Electronic address: zhangw@ntu.edu.cn.

Xianfen Chen (X)

Department of Pharmacy, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China. Electronic address: cxf8448180@ntu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH